ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2024

Abstract Number: 0487

The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis

Jose Felix Restrepo Suarez1, Carlos Lorenzo1, Inmaculada Del rincon2 and Agustin Escalante1, 1UT Health San Antonio, San Antonio, TX, 2UT Health San Antonio, San Antonio

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2024

Keywords: Cardiovascular, Mortality, rheumatoid arthritis, risk factors

Session Information

Date: Saturday, November 16, 2024

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: The triglyceride to HDL cholesterol (TG/HDL) ratio, a recognized surrogate marker of insulin resistance, has emerged as a predictor of cardiovascular (CV) risk. However, its clinical relevance in RA remains unexplored. In this study, we aimed to investigate the prognostic value of the TG/HDL ratio in predicting mortality in RA patients.

Methods: RA patients meeting the 1987 ACR criteria were recruited consecutively from rheumatology practices from 1996 to 2011. Patients were invited to return for periodic follow-up evaluations. At each visit, clinical and laboratory variables were recorded, including measures of RA disease activity, CV risk factors and the occurrence of CV events. All deaths were confirmed with a death certificate. Deaths were classified as having a CV cause if the death certificate included conditions with ICD-9 codes 390-459.

We used logistic regression analysis to examine the association between TG/HDL ratio and all-cause and CV mortality. Results were adjusted for other risk factors including age, sex, smoking status, diabetes, hypertension, and disease activity (measured by DAS28 ESR).

Results: We studied 1211 patients [906 (75%) were women]. The mean follow-up time was 9.959 person-years with 278 deaths (2.7 per 100 person-years) for all-cause mortality. The mean follow-up time for CV mortality was 8745 person-years with 121 deaths (0.3 per 100 person-years).

TG/HDL ratio was associated with an increased risk of both all-cause mortality (OR=1.09, 95% CI 1.00-1.19, p=0.041) (Table 1) and CV mortality (OR=1.21, 95% CI 1.09-1.35, p< 0.001). (Table 2) after adjusting for age, sex, disease activity, diabetes, smoking status, and hypertension.

Conclusion: TG/HDL ratio is an independent risk factor of all cause and CV mortality in RA patients. These findings suggest that the TG/HDL ratio may be a useful biomarker for assessing CV risk among patients with RA, which could lead to improved risk management and reduced CV morbidity and mortality among RA patients. The role of insulin resistance in RA deserves further study.

Supporting image 1

Supporting image 2


Disclosures: J. Restrepo Suarez: None; C. Lorenzo: None; I. Del rincon: None; A. Escalante: None.

To cite this abstract in AMA style:

Restrepo Suarez J, Lorenzo C, Del rincon I, Escalante A. The Triglyceride to HDL Ratio, a Surrogate Marker of Insulin Resistance, Predicts All Cause and Cardiovascular Mortality in Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/the-triglyceride-to-hdl-ratio-a-surrogate-marker-of-insulin-resistance-predicts-all-cause-and-cardiovascular-mortality-in-rheumatoid-arthritis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-triglyceride-to-hdl-ratio-a-surrogate-marker-of-insulin-resistance-predicts-all-cause-and-cardiovascular-mortality-in-rheumatoid-arthritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology